Hansa Biopharma, Svært at tage seriøst når kursen er 114

Reply to Hansa Biopharma, Svært at tage seriøst når kursen er 114 on Fri, 16 Jul 2021 16:57:41 GMT

B.Andersen — Fri, 16 Jul 2021 16:57:41 GMT

Hansa - Analyseopdateringer:

Just a moment...

(proinvestor.com)

Reply to Hansa Biopharma, Svært at tage seriøst når kursen er 114 on Fri, 16 Jul 2021 11:46:16 GMT

Aps_invest — Fri, 16 Jul 2021 11:46:16 GMT

Jep, forpestet af shorting....nu 2,58% .... Hader det pengegriske skidt

Reply to Hansa Biopharma, Svært at tage seriøst når kursen er 114 on Fri, 16 Jul 2021 09:32:43 GMT

Makingmoney — Fri, 16 Jul 2021 09:32:43 GMT

Hansa nok dette som har givet kursfaldet progress and outlook remain most important for Hansa. In the GBS (Guillain-Barré syndrome) trial, 10 out of 30 patients are now enrolled (8 at the earlier Q1), and in the important, (complements Ideflirix) AMR (Antibody-mediated kidney transplant rejection) trial, 12 out of 30 patients are now enrolled (9 at the earlier Q1). The enrolment rate appears to be modest, especially as Hansa's earlier communication is that both studies are expected to be fully enrolled during H2 2021, and this is now modified to H2 2021/H2 2022.

Vi
Morten

Reply to Hansa Biopharma, Svært at tage seriøst når kursen er 114 on Fri, 16 Jul 2021 05:31:35 GMT

joman18 — Fri, 16 Jul 2021 05:31:35 GMT

Måske er den shortet for meget!